Sunday 18 October 2026
Export TTRX’s income statement to Excel — free account
Turn Therapeutics Inc.
TTRX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 343.5% and free cash flow fell 74.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.57
1.02
−8.80%
Follow TTRX
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
1.55 | 0.87 |
Net Debt/EBITDA |
0.50 | 0.96 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.77 | 0.80 |
Capex/Depreciation |
(2.09) | (0.28) |
| 0.00% | (141.67%) | |
| 0.00% | (44.95%) | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(453.44%) | 395.80% |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.40 | 0.08 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(0.05) | (0.10) |
Cash per Share |
0.03 | 0.18 |
Shareholders Equity per Share |
(0.01) | 0.17 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(0.01) | 0.17 |
Free Cash Flow |
(1.46) | (2.72) |
Working Capital |
0.39 | (0.81) |
Capital Expenditures |
(0.10) | (0.15) |
Net Current Asset Value |
(1.13) | (2.28) |
| Other line items | ||
Quick Ratio |
1.23 | 0.85 |
Depreciation/Fixed assets |
0.00 | 0.00 |
Cash ROIC |
(210.13%) | (27.82%) |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(0.05) | (0.09) |
Capex per Share |
0.00 | (0.01) |
Average Payables |
— | 1.80 |
Average Assets |
— | 7.11 |
Average Common Equity |
— | 2.25 |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates